Figure 6. Reelin expression in tumours in mice and clinical data sets.

(a) Reln expression in lung tumours from 7-week-old Pik3ca^WT/flox, Pik3ca^RBD/flox, Pik3ca^WT/− Pik3ca^RBD/− mice treated and untreated with tamoxifen. All these mice harbour an oncogenic mutation in Kras so they develop lung tumours. Tumours were collected 1 week after the end of tamoxifen treatment. Actin expression was used as an internal control for normalization. (b) E-cadherin expression in lung tumours from 7-week-old Pik3ca^WT/flox, Pik3ca^RBD/flox, Pik3ca^WT/− Pik3ca^RBD/− mice treated and untreated with tamoxifen. Tumours were collected 1 week after the end of tamoxifen treatment. Actin expression was used as an internal control for normalization. (c) Representative images of Reln and E-cadherin staining of lung sections from Pik3ca^WT/− Pik3ca^RBD/− mice. (d) Plot representing human RELN expression values from patients with the tumour types indicated in the figure. (e) Kaplan–Meier graph showing overall survival for lung adenocarcinoma patients with low and high expression of RELN. High and low RELN expression was divided by median.